Active rTMS
DevicerTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
NCT Number: NCT06391723
Electroconvulsive therapy (ECT) is one of the most effective treatments for treatment-resistant depression (TRD). However, due to response delay and cognitive impairment, ECT remains an imperfect treatment. In this multicenter, randomized, double-blind, sham-controlled study, our objective is to assess the priming effect of rTMS sessions before ECT on clinical, cognitive and neural response in patients with TRD.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Not applicable
80 patients with TRD will be assigned to active or sham rTMS before ECT treatment. Five sessions of active/sham rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session) before ECT (which was active for all patients) started. Then, from the sixth ECT session, an rTMS session will occur the day before each ECT session. Clinical assessment, cognitive assessment and brain imaging (structural MRI, resting state functional MRI, MR spectroscopy) will take place before and after 10 ECT sessions. Clinical, cognitive and neural changes will be compared between both groups after 10 ECT sessions.
The primary outcome will be the response rate after 10 ECT, i.e. the percentage of patients who achieved a reduction of 50% or more from their initial Hamilton Depression Scale score (HAMD-21 items).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
Sham rTMS will be administered over the left dorsolateral prefrontal cortex
Time frame: Day 0 and Day 40
the percentage of patients who achieved a reduction of 50% or more from their initial Hamilton Depression Scale score (HAMD-21 items)
Time frame: Day 0, Day 4, Day 19, Day 26, Day 40
the relative variation of HAMD-21
Time frame: Day 0, Day 4, Day 19, Day 26, Day 40
Quick Inventory of Depressive Symptomatology
Time frame: Day 4, Day 19, Day 26, Day 40
Assessment of adverse effects with the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale adapted to rTMS (adapted UKU)
Time frame: Day 4, Day 19, Day 26, Day 40
Scores and variations in memory assessed with the Squire Subjective Memory Questionnaire (SSMQ)
Time frame: Day 4, Day 19, Day 26, Day 40
Scores and variations in cognitive functioning assessed with the Cognitive Failures Questionnaire (CFQ)
Time frame: Day 0 and Day 40
Scores and variations assessed with the Mini Mental Status Examination
Time frame: Day 0 and Day 40
Scores and variations assessed with the RL/RI-16 test
Time frame: Day 0 and Day 40
Scores and variations assessed the D2 test of attention
Time frame: Day 0 and Day 40
Scores and variations assessed with the Rey-Osterrieth complex figure test
Time frame: Day 0 and Day 40
Scores and variations assessed with the autobiographical memory test (TEMPau)
Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37
Seizure threshold during ECT
Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37
Seizure duration during ECT
Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37
Postictal Suppression during ECT
Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37
Dose of medication during ECT
Time frame: Day 0 and Day 40
Changes in regional gray matter density measured with 3D MRI
Time frame: Day 0 and Day 40
Changes in cortical thickness measured with 3D MRI
Time frame: Day 0 and Day 40
Changes measured with Resting state functional MRI and spectroscopy MRI
Contact information is provided by the study sponsor or research team.
Centre Hospitalier du Rouvray
Other Gov
Clinical, Cognitive and Neural Effect of Potentiation of Electroconvulsive Therapy (ECT) by Repetitive Transcranial Magnetic Stimulation (rTMS) at 10 ECT in Patients With Characterized Pharmacoresistant Depressive Episode
Acronym: STIMAGNECT2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07594483
Behavior, Behavioral Symptoms
View Trial DetailsNCT07528157
Depressive Disorder, Depressive Disorder, Major
Stanford, California, United States
View Trial DetailsNCT07399756
Depressive Disorder, Depressive Disorder, Major
Ramat Gan, Israel
View Trial DetailsNCT07262008
Depressive Disorder, Depressive Disorder, Major
Toronto, Ontario, Canada
View Trial Details